15
Participants
Start Date
January 3, 2012
Primary Completion Date
April 10, 2015
Study Completion Date
April 10, 2015
Tavokinogene Telseplasmid (tavo)
Patients received intratumoral injection(s) of tavo.
OncoSec Medical System (OMS)
Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle
National Cancer Institute (NCI)
NIH
OncoSec Medical Incorporated
INDUSTRY